Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team
Press release

Cereno Scientific: BioStock: Additional data strengthens Cereno's CS1 in PAH

Cereno Scientific

Following the promising phase IIa results for its drug candidate CS1 in pulmonary arterial hypertension (PAH) in the fall of 2024, Cereno Scientific now delivers comprehensive data that further reinforce the candidate's potential.  The completed clinical study report shows further signs of disease-modifying effects in a disease with limited treatment options. 

Read the article at biostock.se:

https://www.biostock.se/en/2025/02/additional-data-strengthens-cerenos-cs1-in-pah/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/

Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team